A peptide uncoupling CRMP-2 from the presynaptic Ca 2+ channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy

Matthew S. Ripsch, Carrie J. Ballard, May Khanna, Joyce Hurley, Fletcher White, Rajesh Khanna

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Biological, genetic, and clinical data provide compelling proof for N-type voltage-gated calcium channels (CaV2.2) as therapeutic targets for chronic pain. While decreasing channel function is ultimately anti-nociceptive, directly targeting the channel can lead to multiple adverse effects. Targeting regulators of channel activity may facilitate improved analgesic properties associated with channel block and afford a broader therapeutic window. Towards this end, we recently identified a short peptide, designated CBD3, derived from collapsin response mediator protein 2 (CRMP-2) that suppressed inflammatory and neuropathic hypersensitivity by inhibiting CRMP-2 binding to CaV2.2 [Brittain et al.; Nature Medicine 17:822-829 (2011)]. Rodents administered CBD3 intraperitoneally, fused to the HIV TAT protein cell penetrating domain, exhibited antinociception lasting ∼4 hours highlighting potential instability, limited oral bioavailability, and/or rapid elimination of peptide. This report focuses on improving upon the parental CBD3 peptide. Using SPOTScan analysis of synthetic versions of the parental CBD3 peptide, we identified peptides harboring single amino acid mutations that bound with greater affinity to CaV2.2. One such peptide, harboring a phenylalanine instead of glycine (G14F), was tested in rodent models of migraine and neuropathic pain. In vivo laser Doppler blood flowmetry measure of capsaicin-induced meningeal vascular responses related to headache pain was almost completely suppressed by dural application of the G14F peptide. The G14F mutant peptide, administered intraperitoneally, also exhibited greater antinociception in Stavudine (2′-3′-didehydro-2′-3′-dideoxythymidine (d4T)/Zerit®) model of AIDS therapy-induced peripheral neuropathy compared to the parent CBD3 peptide. These results demonstrate the patent translational value of small biologic drugs targeting CaV2.2 for management of clinical pain.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalTranslational Neuroscience
Volume3
Issue number1
DOIs
StatePublished - Mar 2012

Fingerprint

Migraine Disorders
Acquired Immunodeficiency Syndrome
Animal Models
Peptides
Stavudine
Rodentia
Human Immunodeficiency Virus Proteins
Therapeutics
Laser-Doppler Flowmetry
Capsaicin
Neuralgia
Peripheral Nervous System Diseases
Pain Management
Calcium Channels
Drug Delivery Systems
Phenylalanine
Protein Binding
Chronic Pain
Glycine
Biological Availability

Keywords

  • AIDS therapy-induced neuropathic pain
  • Chronic pain
  • CRMP-2
  • d4T/Zerit/Stavudine
  • Meningeal blood flow
  • Migraine model
  • N-type calcium channel
  • NTR
  • Uncoupling peptide

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

A peptide uncoupling CRMP-2 from the presynaptic Ca 2+ channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy. / Ripsch, Matthew S.; Ballard, Carrie J.; Khanna, May; Hurley, Joyce; White, Fletcher; Khanna, Rajesh.

In: Translational Neuroscience, Vol. 3, No. 1, 03.2012, p. 1-8.

Research output: Contribution to journalArticle

@article{8498b0fb9f244baf8efbb4355b42629d,
title = "A peptide uncoupling CRMP-2 from the presynaptic Ca 2+ channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy",
abstract = "Biological, genetic, and clinical data provide compelling proof for N-type voltage-gated calcium channels (CaV2.2) as therapeutic targets for chronic pain. While decreasing channel function is ultimately anti-nociceptive, directly targeting the channel can lead to multiple adverse effects. Targeting regulators of channel activity may facilitate improved analgesic properties associated with channel block and afford a broader therapeutic window. Towards this end, we recently identified a short peptide, designated CBD3, derived from collapsin response mediator protein 2 (CRMP-2) that suppressed inflammatory and neuropathic hypersensitivity by inhibiting CRMP-2 binding to CaV2.2 [Brittain et al.; Nature Medicine 17:822-829 (2011)]. Rodents administered CBD3 intraperitoneally, fused to the HIV TAT protein cell penetrating domain, exhibited antinociception lasting ∼4 hours highlighting potential instability, limited oral bioavailability, and/or rapid elimination of peptide. This report focuses on improving upon the parental CBD3 peptide. Using SPOTScan analysis of synthetic versions of the parental CBD3 peptide, we identified peptides harboring single amino acid mutations that bound with greater affinity to CaV2.2. One such peptide, harboring a phenylalanine instead of glycine (G14F), was tested in rodent models of migraine and neuropathic pain. In vivo laser Doppler blood flowmetry measure of capsaicin-induced meningeal vascular responses related to headache pain was almost completely suppressed by dural application of the G14F peptide. The G14F mutant peptide, administered intraperitoneally, also exhibited greater antinociception in Stavudine (2′-3′-didehydro-2′-3′-dideoxythymidine (d4T)/Zerit{\circledR}) model of AIDS therapy-induced peripheral neuropathy compared to the parent CBD3 peptide. These results demonstrate the patent translational value of small biologic drugs targeting CaV2.2 for management of clinical pain.",
keywords = "AIDS therapy-induced neuropathic pain, Chronic pain, CRMP-2, d4T/Zerit/Stavudine, Meningeal blood flow, Migraine model, N-type calcium channel, NTR, Uncoupling peptide",
author = "Ripsch, {Matthew S.} and Ballard, {Carrie J.} and May Khanna and Joyce Hurley and Fletcher White and Rajesh Khanna",
year = "2012",
month = "3",
doi = "10.2478/s13380-012-0002-4",
language = "English",
volume = "3",
pages = "1--8",
journal = "Translational Neuroscience",
issn = "2081-3856",
publisher = "de Gruyter",
number = "1",

}

TY - JOUR

T1 - A peptide uncoupling CRMP-2 from the presynaptic Ca 2+ channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy

AU - Ripsch, Matthew S.

AU - Ballard, Carrie J.

AU - Khanna, May

AU - Hurley, Joyce

AU - White, Fletcher

AU - Khanna, Rajesh

PY - 2012/3

Y1 - 2012/3

N2 - Biological, genetic, and clinical data provide compelling proof for N-type voltage-gated calcium channels (CaV2.2) as therapeutic targets for chronic pain. While decreasing channel function is ultimately anti-nociceptive, directly targeting the channel can lead to multiple adverse effects. Targeting regulators of channel activity may facilitate improved analgesic properties associated with channel block and afford a broader therapeutic window. Towards this end, we recently identified a short peptide, designated CBD3, derived from collapsin response mediator protein 2 (CRMP-2) that suppressed inflammatory and neuropathic hypersensitivity by inhibiting CRMP-2 binding to CaV2.2 [Brittain et al.; Nature Medicine 17:822-829 (2011)]. Rodents administered CBD3 intraperitoneally, fused to the HIV TAT protein cell penetrating domain, exhibited antinociception lasting ∼4 hours highlighting potential instability, limited oral bioavailability, and/or rapid elimination of peptide. This report focuses on improving upon the parental CBD3 peptide. Using SPOTScan analysis of synthetic versions of the parental CBD3 peptide, we identified peptides harboring single amino acid mutations that bound with greater affinity to CaV2.2. One such peptide, harboring a phenylalanine instead of glycine (G14F), was tested in rodent models of migraine and neuropathic pain. In vivo laser Doppler blood flowmetry measure of capsaicin-induced meningeal vascular responses related to headache pain was almost completely suppressed by dural application of the G14F peptide. The G14F mutant peptide, administered intraperitoneally, also exhibited greater antinociception in Stavudine (2′-3′-didehydro-2′-3′-dideoxythymidine (d4T)/Zerit®) model of AIDS therapy-induced peripheral neuropathy compared to the parent CBD3 peptide. These results demonstrate the patent translational value of small biologic drugs targeting CaV2.2 for management of clinical pain.

AB - Biological, genetic, and clinical data provide compelling proof for N-type voltage-gated calcium channels (CaV2.2) as therapeutic targets for chronic pain. While decreasing channel function is ultimately anti-nociceptive, directly targeting the channel can lead to multiple adverse effects. Targeting regulators of channel activity may facilitate improved analgesic properties associated with channel block and afford a broader therapeutic window. Towards this end, we recently identified a short peptide, designated CBD3, derived from collapsin response mediator protein 2 (CRMP-2) that suppressed inflammatory and neuropathic hypersensitivity by inhibiting CRMP-2 binding to CaV2.2 [Brittain et al.; Nature Medicine 17:822-829 (2011)]. Rodents administered CBD3 intraperitoneally, fused to the HIV TAT protein cell penetrating domain, exhibited antinociception lasting ∼4 hours highlighting potential instability, limited oral bioavailability, and/or rapid elimination of peptide. This report focuses on improving upon the parental CBD3 peptide. Using SPOTScan analysis of synthetic versions of the parental CBD3 peptide, we identified peptides harboring single amino acid mutations that bound with greater affinity to CaV2.2. One such peptide, harboring a phenylalanine instead of glycine (G14F), was tested in rodent models of migraine and neuropathic pain. In vivo laser Doppler blood flowmetry measure of capsaicin-induced meningeal vascular responses related to headache pain was almost completely suppressed by dural application of the G14F peptide. The G14F mutant peptide, administered intraperitoneally, also exhibited greater antinociception in Stavudine (2′-3′-didehydro-2′-3′-dideoxythymidine (d4T)/Zerit®) model of AIDS therapy-induced peripheral neuropathy compared to the parent CBD3 peptide. These results demonstrate the patent translational value of small biologic drugs targeting CaV2.2 for management of clinical pain.

KW - AIDS therapy-induced neuropathic pain

KW - Chronic pain

KW - CRMP-2

KW - d4T/Zerit/Stavudine

KW - Meningeal blood flow

KW - Migraine model

KW - N-type calcium channel

KW - NTR

KW - Uncoupling peptide

UR - http://www.scopus.com/inward/record.url?scp=84858405523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858405523&partnerID=8YFLogxK

U2 - 10.2478/s13380-012-0002-4

DO - 10.2478/s13380-012-0002-4

M3 - Article

VL - 3

SP - 1

EP - 8

JO - Translational Neuroscience

JF - Translational Neuroscience

SN - 2081-3856

IS - 1

ER -